| Attributes | Values |
|---|
| rdf:type
| |
| Description
| - T regulační buňky (Treg) hrají důležitou roli v supresi protinádorové imunity. Byl studován dopad deplece Treg pomocí anti-CD25 protilátky jako adjuvantní terapie při léčbě minimální zbytkové choroby po chirurgickém odstranění myších nádorů asociovaných s HPV-16. Bylo zjištěno, že deplece Treg inhibuje růst rekurencí po operaci MHC I pozitivních i negativních nádorů transplantovaných do syngenních myší. Tyto výsledky dokumentují, že deplece CD25+CD4+ Treg buněk může být využita jako adjuvantní léčba v kombinaci s chirurgickým odstraněním nádoru v experimentálních systémech mimikujících lidské HPV16-asociované, MHC I pozitivní i deficientní nádory. (cs)
- It is generally accepted that T regulatory cells (Treg CD4+CD25+Foxp3+) play an important role in the suppression of tumour immunity. We examined the impact of Treg cell depletion with anti-CD25 antibody as adjuvant therapy in the treatment of minimal residual disease after excision of murine HPV16-associated tumours. We found that the depletion of Treg cells inhibited growth of the recurrences after surgery of HPV16-associated MHC class I+ as well as MHC class I-deficient tumours transplanted in syngeneic mice. These results demonstrate that depletion of CD25+CD4+ Treg cells can be used as an efficient adjuvant treatment improving the results of surgery in the experimental systems mimicking human MHC class I+ and MHC class I-deficient, HPV16-associated neoplasms. Therefore, this therapeutic modality is worth being examined in patients with minimal residual HPV16-associated tumour disease after surgery.
- It is generally accepted that T regulatory cells (Treg CD4+CD25+Foxp3+) play an important role in the suppression of tumour immunity. We examined the impact of Treg cell depletion with anti-CD25 antibody as adjuvant therapy in the treatment of minimal residual disease after excision of murine HPV16-associated tumours. We found that the depletion of Treg cells inhibited growth of the recurrences after surgery of HPV16-associated MHC class I+ as well as MHC class I-deficient tumours transplanted in syngeneic mice. These results demonstrate that depletion of CD25+CD4+ Treg cells can be used as an efficient adjuvant treatment improving the results of surgery in the experimental systems mimicking human MHC class I+ and MHC class I-deficient, HPV16-associated neoplasms. Therefore, this therapeutic modality is worth being examined in patients with minimal residual HPV16-associated tumour disease after surgery. (en)
|
| Title
| - Depletion of Treg cells inhibits minimal residual disease after surgery of HPV16-associated tumours
- Deplece regulačních T buněk potlačuje minimálni zbytkovou chorobu po chirurgickém odstranění nádorů asociovaných s HPV16 (cs)
- Depletion of Treg cells inhibits minimal residual disease after surgery of HPV16-associated tumours (en)
|
| skos:prefLabel
| - Depletion of Treg cells inhibits minimal residual disease after surgery of HPV16-associated tumours
- Deplece regulačních T buněk potlačuje minimálni zbytkovou chorobu po chirurgickém odstranění nádorů asociovaných s HPV16 (cs)
- Depletion of Treg cells inhibits minimal residual disease after surgery of HPV16-associated tumours (en)
|
| skos:notation
| - RIV/68378050:_____/06:00044812!RIV07-GA0-68378050
|
| http://linked.open.../vavai/riv/strany
| |
| http://linked.open...avai/riv/aktivita
| |
| http://linked.open...avai/riv/aktivity
| - P(GA301/04/0492), Z(AV0Z50520514)
|
| http://linked.open...iv/cisloPeriodika
| |
| http://linked.open...vai/riv/dodaniDat
| |
| http://linked.open...aciTvurceVysledku
| |
| http://linked.open.../riv/druhVysledku
| |
| http://linked.open...iv/duvernostUdaju
| |
| http://linked.open...titaPredkladatele
| |
| http://linked.open...dnocenehoVysledku
| |
| http://linked.open...ai/riv/idVysledku
| - RIV/68378050:_____/06:00044812
|
| http://linked.open...riv/jazykVysledku
| |
| http://linked.open.../riv/klicovaSlova
| - HPV16; residual tumour disease; Treg cells (en)
|
| http://linked.open.../riv/klicoveSlovo
| |
| http://linked.open...odStatuVydavatele
| |
| http://linked.open...ontrolniKodProRIV
| |
| http://linked.open...i/riv/nazevZdroje
| - International Journal of Oncology
|
| http://linked.open...in/vavai/riv/obor
| |
| http://linked.open...ichTvurcuVysledku
| |
| http://linked.open...cetTvurcuVysledku
| |
| http://linked.open...vavai/riv/projekt
| |
| http://linked.open...UplatneniVysledku
| |
| http://linked.open...v/svazekPeriodika
| |
| http://linked.open...iv/tvurceVysledku
| - Reiniš, Milan
- Bieblová, Jana
- Bubeník, Jan
- Šímová, Jana
- Rosalia, Rodney Alexander
- Frič, Jan
|
| http://linked.open...n/vavai/riv/zamer
| |
| issn
| |
| number of pages
| |
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)